"Alan Mendelson has a national reputation for his work with early stage and established companies in the life sciences industry. He brings an enviable level of experience to the table for his clients and is 'highly responsive, and the quality of his work is top-notch,' according to sources."


Chambers USA 2016

Alan C. Mendelson

Silicon Valley
  • 140 Scott Drive
  • Menlo Park, CA 94025
  • USA

Alan Mendelson represents emerging and public growth companies, primarily in the life sciences industry. He served as the Co-Chair of the firm’s Emerging Companies Practice from 2001 to 2013 and currently is Co-Chair of the Life Sciences Industry Group. Mr. Mendelson has handled and supervised a variety of major business transactions, including:

  • Venture capital financings
  • Private placements 
  • Public offerings
  • Mergers and acquisitions
  • Joint ventures
  • Strategic collaborations 
  • Commercial transactions

Mr. Mendelson currently serves on the Board of Directors of the California Life Sciences Association (CLSA), the Board of Trustees of the UC Berkeley Foundation, and the Board of Advisors for the UC Berkeley Department of Chemistry. Mr. Mendelson previously served on the Board of Directors of the Biotechnology Industry Organization (BIO), the Board of Trustees of The Scripps Research Institute, and the BayBio Board of Directors. He serves as the corporate secretary for many public and private companies.

Mr. Mendelson is a member of the UC Innovation Council to advise UC President Janet Napolitano on technology and entrepreneurship initiatives for the UC system.

From 2009 to 2011, Mr. Mendelson served as President of the Cal Alumni Association. Previously, Mr. Mendelson served as the President of the National Kidney Foundation of Northern California, Inc., as a member of the Board of Regents of the University of California and as a member of the Board of Overseers Visiting Committee of Harvard Law School.

Mr. Mendelson serves as a member of the Major Gifts Council for the Lucile Packard Foundation for Children's Health and as a member of the Board of the American Friends of Rambam Medical Center, Haifa, Israel.

Mr. Mendelson was recently a guest on Hsu Untied – A podcast series on lawyers and other Special Guests. Listen here.


As counsel to Amgen from its inception in 1980 through 2006, Mr. Mendelson handled numerous transactions, including its initial public offering in 1983; its joint venture with Kirin; a number of major research and development partnerships; its European convertible debt deal; and its co-promotion agreement for Europe with F. Hoffman-La Roche. He also served as Amgen’s Secretary and Acting General Counsel.

Mr. Mendelson currently serves as principal outside or general counsel to numerous companies including:

  • Antiva Biosciences, Inc.
  • Ardelyx, Inc.
  • Chrono Therapeutics Inc.
  • Coherus BioSciences, Inc.
  • Corcept Therapeutics, Inc.
  • Corvus Pharmaceuticals, Inc.
  • Gritstone Oncology, Inc.
  • Intuitive Surgical, Inc.
  • Intuity Medical, Inc.
  • Mellanox Technologies, Ltd.
  • Mirna Therapeutics, Inc.
  • OncoMed Pharmaceuticals, Inc.
  • Prothena Corporation plc.
  • Relypsa, Inc.
  • Second Genome, Inc.
  • Singulex, Inc.
  • TiVo Inc.
  • Verrica Pharmaceuticals, Inc.

In the public offering arena, Mr. Mendelson has been counsel to a number of investment banks in offerings for emerging growth companies, including:

  • Citibank
  • Credit Suisse
  • CSFB
  • DeutschBank
  • Goldman Sachs
  • Jefferies & Co.
  • Leerink
  • Morgan Stanley
  • Piper Jaffray

As company counsel he has handled public offerings for such notable companies as:

  • Amgen, Inc. 
  • Ardelyx, Inc.
  • Avalanche Biotechnologies, Inc.
  • Aviron, Inc. 
  • Axys Pharmaceuticals, Inc. 
  • Coherus BioSciences, Inc.
  • Complete Genomics, Inc. 
  • Corcept Therapeutics Inc.
  • CV Therapeutics, Inc. 
  • Geron Corporation
  • Intuitive Surgical, Inc. 
  • InterMune, Inc. 
  • Kythera Biopharmaceuticals, Inc.
  • Mellanox Technologies Ltd. 
  • Novacea, Inc. 
  • OncoMed Pharmaceuticals, Inc.
  • Pharmacyclics, Inc.
  • Prothena plc.
  • Qualcomm, Inc. 
  • Relypsa, Inc.
  • Renovis, Inc.
  • Sarepta Therapeutics, Inc.
  • TiVo, Inc.
  • Transcept Pharmaceuticals, Inc.
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.